PepGen, Inc. (NASDAQ:PEPG) Receives $11.50 Consensus Target Price from Brokerages

PepGen, Inc. (NASDAQ:PEPG) has earned an average rating of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $11.50.

PEPG has been the topic of several research reports. Wedbush cut their price objective on PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating on shares of PepGen in a research report on Thursday, May 21st. Craig Hallum began coverage on PepGen in a research note on Tuesday, June 16th. They issued a “buy” rating and a $11.00 target price for the company. Weiss Ratings lowered PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research note on Sunday, June 7th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of PepGen during the first quarter valued at approximately $122,000. Woodline Partners LP bought a new position in PepGen during the 1st quarter valued at approximately $1,097,000. Marshall Wace LLP purchased a new position in PepGen during the second quarter valued at $44,000. Qube Research & Technologies Ltd bought a new stake in PepGen in the second quarter worth $81,000. Finally, Bridgeway Capital Management LLC boosted its holdings in PepGen by 61.5% in the second quarter. Bridgeway Capital Management LLC now owns 91,923 shares of the company’s stock worth $102,000 after acquiring an additional 35,000 shares in the last quarter. 58.01% of the stock is owned by hedge funds and other institutional investors.

PepGen Trading Up 0.6%

Shares of NASDAQ PEPG opened at $1.81 on Friday. The firm has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $3.84. PepGen has a 12 month low of $1.01 and a 12 month high of $7.80. The firm has a market capitalization of $125.20 million, a PE ratio of -1.03 and a beta of 1.88.

PepGen (NASDAQ:PEPG) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05. On average, sell-side analysts predict that PepGen will post -1.2 earnings per share for the current year.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).